5-MeO-DiPT (5-methoxy-N,N-diisopropyltryptamine), known by the street names "Foxy" and**"Foxy Methoxy,"** is a synthetic tryptamine psychedelic first synthesized byAlexander Shulgin around 1980 and documented in his 1997 book TiHKAL: Tryptamines I Have Known and Loved. The compound occupies a distinctive niche among tryptamine psychedelics due to its unusually pronounced tactile and somatic effects --- many users report that the body sensations dominate the experience, with strong buzzing or electrical-feeling energy throughout the body, heightened tactile sensitivity, and intensified physical pleasure that can take on an erotic quality .
Unlike most psychedelic tryptamines where visual effects take center stage, 5-MeO-DiPT is known for producing relatively modest visuals compared to its intense body load. At lower doses (6--12 mg oral), the experience tends toward empathogenic warmth with enhanced tactile sensation; at higher doses, the body effects can become overwhelming and uncomfortable, with reports of muscle tension, gastrointestinal distress, and cardiovascular stimulation. This steep dose-response curve for side effects makes careful dosing particularly important .
Pharmacologically, 5-MeO-DiPT acts as an agonist at 5-HT2A, 5-HT2C, and 5-HT1A receptors and is also a competitive inhibitor of theserotonin transporter (SERT), which may contribute to its empathogenic and body-centric effects. OnApril 4, 2003, the U.S. DEA placed 5-MeO-DiPT intoSchedule I via emergency scheduling, alongside alpha-methyltryptamine (AMT), citing increasing reports of recreational use and hospitalizations .
References
Shulgin A, Shulgin A. TiHKAL: Tryptamines I Have Known and Loved. Transform Press. 1997. Smolinske SC, et al. Foxy methoxy: a new drug of abuse. J Med Toxicol. 2005;1(1):22-25. US DEA. Schedules of Controlled Substances: Temporary Placement of 5-MeO-DiPT and AMT into Schedule I. Federal Register. 2003;68(65):16427-16430.
Safety at a Glance
High Risk- General Principles
- Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual se...
- Toxicity: The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific contex...
- Dangerous with: PCP, Cocaine
- Overdose risk: Fatal overdose from 5-MeO-DiPT alone, at doses within the typical recreational range, is extremel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 8 hrsHow It Feels
The onset of 5-MeO-DiPT — known colloquially as Foxy — announces itself through the body with unmistakable intensity. Within twenty to forty minutes of ingestion, a powerful physical buzzing takes hold: a deep, electric vibration that runs through the muscles and skin, concentrated especially in the torso and genitals. Nausea is common and can be significant, sometimes accompanied by intestinal discomfort. Simultaneously, a warmth floods upward through the body, and the sense of touch begins to amplify dramatically. Every point of contact — clothing against skin, fingers on a surface, the weight of the body against a chair — becomes intensely detailed and pleasurable.
As the come-up progresses, the tactile enhancement becomes the dominant feature. Touch takes on an almost synesthetic quality: physical sensations seem to carry color and emotional content, and the boundaries between tactile perception and emotional experience begin to blur. Erotic sensation is powerfully amplified; even non-sexual touch can provoke waves of physical pleasure. Auditory effects emerge alongside the tactile ones: sounds become richer and more resonant, music acquires an almost physical presence, and there may be subtle pitch distortions similar to those produced by DiPT, though generally less pronounced. Visual effects are modest — mild color enhancement and soft patterning — and play a distinctly secondary role.
At the peak, roughly ninety minutes to two hours in and lasting two to three hours, Foxy occupies a unique space in the tryptamine family. The experience is intensely embodied and sensual, with a warmth and physicality that has more in common with empathogens like MDMA than with classical psychedelics. The headspace is stimulated and engaged, socially fluent and emotionally open. There is a notable empathogenic quality: warmth toward others, ease of conversation, and a sense of interpersonal connection that feels genuine and deep. The body, however, demands attention — the physical stimulation is persistent and powerful, and nausea or gastrointestinal discomfort can intrude.
The comedown spans two to three hours and can leave behind significant physical fatigue. The intense tactile enhancement fades gradually, and the body feels spent, as though it has been running at high capacity. A mild headache is not uncommon. The afterglow is warm but tired, and sleep may be difficult despite exhaustion due to residual stimulation. The overall experience is distinctive: more body than mind, more sensual than cerebral, and utterly unlike anything else in the tryptamine family.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(16)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Decreased blood pressure— Decreased blood pressure (hypotension) is a drop in arterial blood pressure below normal levels, com...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach bloating— Stomach bloating is the uncomfortable distension of the abdomen resulting from gas accumulation, flu...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(13)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Pharmacology
5-MeO-DiPT presents a pharmacological profile that is considerably more complex than the typical "5-HT2A agonist" label applied to most psychedelic tryptamines. While it does engage the serotonin 2A receptor, its most distinctive pharmacological feature is potent serotonin transporter (SERT) inhibition -- an action more commonly associated with MDMA and antidepressants than with classical psychedelics .
Serotonin Transporter Inhibition
Research published in Toxicology and Applied Pharmacology demonstrated that 5-MeO-DiPT is a competitive inhibitor of SERT with high affinity, inhibiting serotonin uptake at concentrations comparable to those required by cocaine . This means that in addition to directly activating serotonin receptors, 5-MeO-DiPT blocks the recycling of serotonin from the synaptic cleft, effectively flooding serotonergic synapses from two directions simultaneously. This dual action -- direct receptor agonism plus reuptake inhibition -- likely accounts for the compound's characteristically intense body effects and its reputation for producing a heavier serotonergic "body load" than structurally similar tryptamines that lack significant SERT activity.
Receptor Profile
Beyond SERT, 5-MeO-DiPT displays high affinity for 5-HT2A,5-HT2C, and5-HT1A receptors, functioning as an agonist at all three . Its dual action at both the serotonin transporter and serotonin 5-HT1A receptor has been confirmed in mouse striatum and prefrontal cortex, where it simultaneously increases extracellular serotonin (via SERT inhibition) and directly activates postsynaptic receptors . It shows lower but measurable affinity for thedopamine transporter (DAT), which may contribute to its stimulant and empathogenic qualities, and it increases in vivo release of dopamine, serotonin, and glutamate in rat striatum, nucleus accumbens, and frontal cortex .
The Body-Load Pharmacology
The intense physical effects that define the 5-MeO-DiPT experience -- nausea, muscle tension, cardiovascular stimulation (tachycardia, hypertension), and gastrointestinal disturbance -- arise from this combinatorial pharmacology. Elevated peripheral serotonin from SERT inhibition activates gut 5-HT3 and 5-HT4 receptors, driving nausea and GI motility. Simultaneous 5-HT2A agonism in smooth muscle contributes to vasoconstriction and the sensation of physical tension. The stimulant properties (mydriasis, tachycardia, hyperthermia) reflect both serotonergic and dopaminergic activation .
Neurotoxicity Concerns
Animal studies have raised concerns about 5-MeO-DiPT's neurotoxic potential. Research in rats demonstrated that a single administration produced DNA single- and double-strand breaks that persisted for up to 60 days after treatment, suggesting sustained oxidative damage to neural tissue -- a finding not typically associated with classical serotonergic psychedelics . The clinical significance of these findings in humans at recreational doses remains unclear, but they distinguish 5-MeO-DiPT from the generally favorable neurotoxicity profiles of compounds like psilocybin and LSD.
References
Nagai F, et al. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicology and Applied Pharmacology. 2007;221(2):216-224. Herian M, et al. Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex. Pharmacological Reports. 2021;73:856-867. Noworyta-Sokolowska K, et al. Neurotoxic effects of 5-MeO-DIPT: a psychoactive tryptamine derivative in rats. Neurotoxicity Research. 2016;30:606-619. Noworyta-Sokolowska K, et al. 5-MeO-DIPT: pharmacology and neurotoxicity. Current Neuropharmacology. 2019;17(5):420-430.
Detection Methods
Urine Detection
5-MeO-DiPT is not targeted by standard immunoassay-based urine drug screens. 5-MeO-substituted tryptamines are metabolized primarily through hepatic pathways involving CYP2D6 and monoamine oxidase enzymes, producing demethylated and hydroxylated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect these metabolites in urine for approximately 24 to 48 hours after ingestion, though the detection window varies with dose and individual metabolic rate. The short duration of action of most 5-MeO tryptamines correlates with a relatively brief detection window.
Blood and Serum Detection
Blood detection windows for 5-MeO-DiPT are short, typically 2 to 8 hours after administration depending on the route. Smoked or insufflated routes produce rapid peak concentrations followed by swift clearance, while oral administration (particularly with MAO inhibition) extends both the effect and detection windows. LC-MS/MS is required for reliable blood quantification at the low nanogram-per-milliliter concentrations typical of 5-MeO tryptamines.
Standard Drug Panel Inclusion
5-MeO-DiPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. 5-MeO tryptamines do not cross-react with any standard immunoassay panel targets. There is no reliable cross-reactivity with amphetamine, opiate, or any other standard immunoassay. Detection requires a specific request for tryptamine testing at a laboratory with novel psychoactive substance capabilities.
Confirmatory Methods
Definitive identification of 5-MeO-DiPT requires LC-MS/MS or GC-MS analysis with compound-specific reference standards. Some forensic toxicology laboratories include 5-MeO-DMT in their expanded tryptamine panels, but coverage of other 5-MeO variants is less common. Bufotenin (5-HO-DMT), a metabolite of 5-MeO-DMT, may also be targeted. Quantitative analysis requires validated methods, as the structural similarity among 5-MeO tryptamines can complicate chromatographic separation without optimized conditions.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with 5-MeO-DiPT, confirming the presence of an indole ring characteristic of all tryptamines. This is the primary field identification tool and should always be the first test performed. The Hofmann reagent provides a confirmatory blue reaction. The Marquis reagent typically shows no reaction or a faint yellow to brown discoloration with 5-MeO tryptamines. Because 5-MeO tryptamines can be significantly more potent by weight than 4-substituted analogs, reagent testing alone is not sufficient for safe use. Quantitative analysis and accurate dosing are critically important for this subclass.
Interactions
| Substance | Status | Note |
|---|---|---|
| PCP | Dangerous | — |
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| 2C-x | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
The history of 5-MeO-DiPT is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, 5-MeO-DiPT was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
5-MeO-DiPT exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Harm Reduction
General Principles
- Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual sensitivity varies enormously.
- Test your substances: Use reagent test kits to verify identity and check for dangerous adulterants. Consider using drug checking services where available.
- Research thoroughly: Understand expected dose ranges, duration, potential interactions, and contraindications before use.
- Never use alone: Have a trusted, sober person present, especially with new substances or higher doses.
- Set and setting: Your mindset and environment profoundly influence the experience. Choose a safe, comfortable environment and ensure you're in a stable psychological state.
5-MeO-DiPT-Specific Harm Reduction
- Integration: Allow time between experiences to integrate insights. Using psychedelics too frequently can lead to psychological distress.
- Trip sitter: A sober, experienced sitter is invaluable, especially at higher doses. They should be briefed on what to expect and how to help.
- Difficult experiences: If anxiety occurs, change the setting (different room, different music), practice slow breathing, and remember the effects are temporary. Having a benzodiazepine available (not for routine use) can provide reassurance.
- Duration planning: Ensure you have no obligations for the full duration plus several hours of recovery time.
- Contraindications: Avoid combining with lithium (seizure risk), tramadol (seizure risk), or SSRIs (reduced effects, potential serotonin issues). Those with personal or family history of psychotic disorders should exercise extreme caution.
Toxicity & Safety
The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context, and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a research chemical with very little history of human usage. The neurotoxic effects have been studied in rats.
Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Overdose
Excessive doses have caused nausea, vomiting, agitation, decreased blood pressure, pupil dilation, increased heart rate, and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man, and another one died 3–4 hours after an apparent rectal overdose. A 24-year-old man also died of this compound being administered into the colon.
Tolerance and addiction potential
Like other serotonergic psychedelics, 5-MeO-DiPT is not habit-forming.
Tolerance to the effects of 5-MeO-DiPT builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DiPT, all psychedelics will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
2C-T-X - Both classes of compounds can be unpredictable alone.
2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
DXM - Little information exists about this combination.
Tramadol - Increased risk of serotonin syndrome.
aMT - Increased risk of serotonin syndrome.
MAOIs - Increased risk of serotonin syndrome.
PCP - Little information exists about this combination. May increase risk of psychosis and excessive stimulation. 5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI). 5-MeO-DiPT and MAOIs are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 5-MeO-DiPT alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
China: 5-MeO-DiPT is illegal in China.
Denmark: 5-MeO-DiPT is illegal in Denmark.
Germany: 5-MeO-DiPT is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of October 10, 2000. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Greece: 5-MeO-DiPT is illegal in Greece.
Japan: 5-MeO-DiPT is illegal in Japan.
Latvia: 5-MeO-DiPT is illegal in Latvia.
New Zealand: 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.
Singapore: 5-MeO-DiPT is illegal in Singapore.
Sweden: 5-MeO-DiPT is illegal in Sweden.
Switzerland: 5-MeO-DiPT is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
United States: 5-MeO-DiPT is a Schedule 1 controlled substance. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.
Responsible use
Research chemical
Tryptamine
DiPT
5-MeO-DiPT (Wikipedia)
5-MeO-DiPT (Erowid Vault)
5-MeO-DiPT (TiHKAL / Isomer Design)
Discussion
The Big & Dandy 5-MeO-DiPT Thread (Bluelight)
Experience Reports (1)
Tips (5)
If you experience anxiety or thought loops on 5-MeO-DiPT, change your physical environment: move to a different room, go outside, change the music, or hold something cold. A change of scenery can instantly shift a difficult headspace.
Set and setting are paramount with 5-MeO-DiPT. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
Start with a low dose of 5-MeO-DiPT if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 5-MeO-DiPT and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 5-MeO-DiPT for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 5-MeO-DiPT - TripSit Factsheet
TripSit factsheet for 5-MeO-DiPT
tripsit - 5-MeO-DiPT - Wikipedia
Wikipedia article on 5-MeO-DiPT
wikipedia